Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC

被引：0
|
作者：
Nassar, Amin
Mouw, Kent William
Liu, Chia-Jen
Lundgren, Kevin
Van Allen, Eliezer Mendel
Harshman, Lauren Christine
Pomerantz, Mark
Preston, Mark A.
Wei, Xiao X.
McGregor, Bradley Alexander
Choudhury, Atish Dipankar
Bellmunt, Joaquim
Choueiri, Toni K.
Kwiatkowski, David J.
Sonpavde, Guru
机构：
[1] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Brookline, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[5] David Grant Med Ctr, Benicia, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4539
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
    Nassar, Amin H.
    Mouw, Kent W.
    Jegede, Opeyemi
    Shinagare, Atul B.
    Kim, Jaegil
    Liu, Chia-Jen
    Pomerantz, Mark
    Harshman, Lauren C.
    Van Allen, Eliezer M.
    Wei, Xiao X.
    McGregor, Bradley
    Choudhury, Atish D.
    Preston, Mark A.
    Dong, Fei
    Signoretti, Sabina
    Lindeman, Neal I.
    Bellmunt, Joaquim
    Choueiri, Toni K.
    Sonpavde, Guru
    Kwiatkowski, David J.
    BRITISH JOURNAL OF CANCER, 2020, 122 (04) : 555 - 563
  • [2] A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
    Amin H. Nassar
    Kent W. Mouw
    Opeyemi Jegede
    Atul B. Shinagare
    Jaegil Kim
    Chia-Jen Liu
    Mark Pomerantz
    Lauren C. Harshman
    Eliezer M. Van Allen
    Xiao X. Wei
    Bradley McGregor
    Atish D. Choudhury
    Mark A. Preston
    Fei Dong
    Sabina Signoretti
    Neal I. Lindeman
    Joaquim Bellmunt
    Toni K. Choueiri
    Guru Sonpavde
    David J. Kwiatkowski
    British Journal of Cancer, 2020, 122 : 555 - 563
  • [3] The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation
    Bardhan, Kankana
    Anagnostou, Theodora
    Boussiotis, Vassiliki A.
    FRONTIERS IN IMMUNOLOGY, 2016, 7
  • [4] First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).
    Agarwal, Archana
    Pond, Gregory Russell
    Drakaki, Alexandra
    Lee, Jae-Lyun
    Bilen, Mehmet Asim
    Di Lorenzo, Giuseppe
    Grivas, Petros
    Ornstein, Moshe Chaim
    Barata, Pedro C.
    Gupta, Shilpa
    Hussain, Syed A.
    Curran, Catherine
    Garcia, Jorge A.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay
    Cimadamore, Alessia
    Massari, Francesco
    Santoni, Matteo
    Lopez-Beltran, Antonio
    Cheng, Liang
    Scarpelli, Marina
    Montironi, Rodolfo
    Moch, Holger
    CURRENT DRUG TARGETS, 2020, 21 (16) : 1664 - 1671
  • [6] Trends in clinical development for PD-1/PD-L1 inhibitors
    Yu, Jia Xin
    Hodge, Jeffrey P.
    Oliva, Cristina
    Neftelinov, Svetoslav T.
    Hubbard-Lucey, Vanessa M.
    Tang, Jun
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (03) : 163 - 164
  • [7] PD1 and PD-L1 expression in glioblastoma
    Berghoff, Anna Sophie
    Kiesal, Barbara
    Widhalm, Georg
    Rajky, Orsolya
    Ricken, Garda
    Woehrer, Adelheid
    Dieckmann, Karin
    Filipits, Martin
    Zielinski, Christoph
    Marosi, Christine
    Hainfellner, Johannes A.
    Preusser, Matthias
    Wick, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] PD-L1 and PD1 Expression in Lymphomas
    Gatalica, Zoran
    Bilalovic, Nurija
    Vranic, Semir
    Arguello, David
    Reddy, Sandeep
    Ghosh, Nilanjan
    BLOOD, 2015, 126 (23)
  • [9] ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors
    Park, W.
    Kwon, D.
    Desai, A.
    Florou, V.
    Saravia, D.
    Warsch, J.
    Chae, Y. K.
    Ishkanian, A.
    Jahanzeb, M.
    Mudad, R.
    Lopes, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2004 - S2004
  • [10] Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors
    Lu, Jia-Cheng
    Zeng, Hai-Ying
    Sun, Qi-Man
    Meng, Qing-Nan
    Huang, Xiao-Yong
    Zhang, Peng-Fei
    Yang, Xuan
    Peng, Rui
    Gao, Chao
    Wei, Chuan-Yuan
    Shen, Ying-Hao
    Cai, Jia-Bing
    Dong, Rui-Zhao
    Shi, Ying-Hong
    Sun, Hui-Chuan
    Shi, Yujiang G.
    Zhou, Jian
    Fan, Jia
    Ke, Ai-Wu
    Yang, Liu-Xiao
    Shi, Guo-Ming
    THERANOSTICS, 2019, 9 (16): : 4678 - 4687
12345